BiotechTube

QUTENZA + Lidocaine + Tramadol

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

or Peripheral Nerve Injury (PNI)

Conditions

or Peripheral Nerve Injury (PNI), Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN)

Trial Timeline

Jul 6, 2011 → Apr 25, 2012

NCT ID
NCT01416116

About QUTENZA + Lidocaine + Tramadol

QUTENZA + Lidocaine + Tramadol is a approved stage product being developed by Astellas Pharma for or Peripheral Nerve Injury (PNI). The current trial status is completed. This product is registered under clinical trial identifier NCT01416116. Target conditions include or Peripheral Nerve Injury (PNI), Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN).

What happened to similar drugs?

19 of 20 similar drugs in or Peripheral Nerve Injury (PNI) were approved

Approved (19) Terminated (4) Active (1)
✅Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgYuhanApproved
✅Anplag Tab. 100mg bid + Anplag Tab. 100mg tidYuhanApproved
✅Qutenza + PregabalinAstellas PharmaApproved
✅Duloxetine + Pregabalin + PlaceboShionogiApproved
✅Mecobalamin IV Injection + Mecobalamin IM injection + Mecobalamin IV or IM injectionEisaiApproved
✅Ticagrelor + clopidogrelAstraZenecaApproved
✅Gabapentin/B-complex + PregabalinMerckApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01416116ApprovedCompleted

Competing Products

20 competing products in or Peripheral Nerve Injury (PNI)

See all competitors
ProductCompanyStageHype Score
SON-080Sonnet BioTherapeuticsPhase 1/2
18
LY3857210 + PlaceboEli LillyPhase 2
35
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgYuhanApproved
43
YHD1119 + LyricaYuhanPhase 1
29
Anplag Tab. 100mg bid + Anplag Tab. 100mg tidYuhanApproved
43
YHD1119 + LyricaYuhanPhase 1
29
YHD1119 + LyricaYuhanPhase 3
40
YHD1119 300mg + YHD1119 300mgYuhanPhase 1
29
DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsuleDaiichi SankyoPhase 2
35
edoxaban + Clopidogrel + AspirinDaiichi SankyoPhase 2
35
DS-5565 + placeboDaiichi SankyoPhase 3
40
Mirogabalin + PlaceboDaiichi SankyoPhase 3
40
DS-5565Daiichi SankyoPhase 3
40
Valemetostat TosylateDaiichi SankyoPhase 2
39
ASP3662 + pregabalin + ASP3662 placebo + pregabalin placeboAstellas PharmaPhase 2
27
QutenzaAstellas PharmaPre-clinical
26
Qutenza exposureAstellas PharmaPre-clinical
26
QUTENZAAstellas PharmaPhase 3
40
Qutenza + PregabalinAstellas PharmaApproved
43
Capsaicin 8% + PlaceboAstellas PharmaPhase 3
40